The Global Health EDCTP3 Joint Undertaking (GH EDCTP3) builds on the first and second European and Developing Countries Clinical Trials Partnership programmes. This new joint undertaking (JU) is a partnership between the EU and the EDCTP Association, whose members are several European and African countries. The partnership will deliver new solutions for reducing the burden of infectious diseases in SSA and strengthen research capacities to prepare and respond to re-emerging infectious diseases in this region and across the world.

This topic focuses on Tackling Antimicrobial Resistance (AMR) through R&D in novel and existing antimicrobials. Tackling AMR requires multi-modal interventions, the collaboration of many disciplines and countries. Antimicrobial stewardship (AMS) could further reduce the burden of drug-resistant infection. The WHO defines AMS as a coherent set of integrated actions which promote the responsible and appropriate use of antimicrobials to help improve patient outcomes across the continuum of care. Responsible and appropriate use of antimicrobials includes prescribing only when needed, selection of the optimal drug regime, drug dosing, route of administration and duration of treatment following proper and optimized diagnosis. These actions are complemented by the implementation of infection prevention and control (IPC), enhancing water, sanitation and hygiene (WASH), and optimizing vaccination coverage.

AMR is one of the Global Health issues which can hugely benefit from the employment of the One Health approach. AMR transmission is a critical global problem affecting humans, the environment, and animals. Hence, proposals need to have the One Health approach at their centre.

Furthermore, the availability and access to existing antibiotics is also a challenge. In particular, efforts to ensure equitable access to antibiotics in LMICs that experience the highest burden of AMR, are needed.

Expected EU Contribution per project: €6.000.000

• Health
• Research, Technological Development and Innovation

• Central Government
• International Organisations
• Legal Entities
• Other Beneficiaries
• Researchers/Research Centers/Institutions
• State-owned Enterprises

Applicants are reminded of the expectation that proposals should come from research consortia with a strong representation of institutions and researchers from sub-Saharan African countries, including involvement of Lranco/Lusophone countries if possible. Applicants are also reminded of the expectation of reaching out to organisations in countries with relatively lower research capacities.

To become a beneficiary, legal entities must be eligible for funding.

To be eligible for funding, applicants must be established in one of the following countries:

• The Member States of the European Union, including their outermost regions: Austria, Belgium, Bulgaria, Croatia, Cyprus, Czechia, Denmark, Estonia, Finland, France, Germany, Greece, Hungary, Ireland, Italy, Latvia, Lithuania, Luxembourg, Malta, Netherlands, Poland, Portugal, Romania, Slovakia, Slovenia, Spain, Sweden;
• The Overseas Countries and Territories (OCTs) linked to the Member States: Aruba (NL), Bonaire (NL), Curação (NL), French Polynesia (FR), French Southern and Antarctic Territories (FR), Greenland (DK), New Caledonia (FR), Saba (NL), Saint Barthélemy (FR), Sint Eustatius (NL), Sint Maarten (NL), St. Pierre and Miquelon (FR), Wallis and Futuna Islands (FR);
• Countries associated to Horizon Europe: Albania, Armenia, Bosnia and Herzegovina, Faroe Islands, Georgia, Iceland, Israel, Kosovo, Moldova, Montenegro, New Zealand (associated to Pillar II ‘Global Challenges and European Industrial Competitiveness’ as from the Work Programmes 2023 onwards, including for the institutionalised European partnerships), North Macedonia, Norway, Serbia, Tunisia, Turkey, Ukraine.

Until association agreements start producing legal effects either through provisional application or their entry into force, transitional arrangements apply. The transitional arrangements apply, at the time of the adoption of this Work Programme, with regard to the following countries and legal entities established in these countries, with which association negotiations are being processed or where association is imminent):

1. Canada

2. Morocco

• The following countries which are constituent states of the EDCTP Association: Benin, Burkina Faso, Cameroon, Côte d’Ivoire, Democratic Republic of the Congo, Ethiopia, Gabon, The Gambia, Ghana, Guinea-Bissau, Guinea-Conakry, Kenya, Liberia, Malawi, Mali, Mozambique, Niger, Nigeria, Republic of the Congo, Rwanda, Senegal, Sierra Leone, Somalia, South Africa, Tanzania, Uganda, Zambia, Zimbabwe.

Consortium composition

Unless otherwise provided for in the specific call conditions, for all actions, due to the policy objectives of the Global Health EDCTP3 JU, legal entities forming a consortium are eligible to participate in actions under the programme provided that the consortium includes:

• At least three legal entities independent from each other and established in different countries, where legal entities are eligible to receive funding;
• At least one independent legal entity established in a Member State or an associated country; and
• At least one independent legal entity established in a sub-Saharan African (SSA) country that is a member of the EDCTP Association.

This condition applies to both Research and Innovation Actions (RIA) and Coordination and Support Actions (CSA).

Specific cases:

Affiliated entities — Affiliated entities (i.e. entities with a legal or capital link to a beneficiary which participate in the action with similar rights and obligations to the beneficiaries, but which do not sign the grant agreement and therefore do not become beneficiaries themselves) are allowed, if they are eligible for participation and funding.

Associated partners — Entities not eligible for funding (and therefore not able to participate as beneficiaries) may participate as associated partners, unless specified otherwise in the specific call conditions.

International organisations – International European research organisations are eligible to receive funding. Other international organisations are not eligible to receive funding unless their participation is considered essential for implementing the action by the granting authority. International organisations with headquarters in a Member State or associated country are eligible to receive funding when provided for in the specific call conditions.

EDCTP – Europe Office
Postal and visiting address: Anna van Saksenlaan 51, 2593 HW The Hague, The Netherlands
Telephone: +31 70 344 0880

EDCTP – Africa Office
Postal address: P.O. Box 19070, Tygerberg 7505, Cape Town, South Africa
Visiting address: Francie van Zijl Drive, Parowvallei 7505, Cape Town, South Africa
Telephone: +27 21 938 0690
Fax: +27 21 938 0569

Contact Form in the website

• Funding&Tenders
• GH EDCTP3 - WP 2024 Annex1A - Calls for Proposals
• GH EDCTP3 - WP 2024, Global Health EDCTP3 Work Programme 2024)